One example is CXR-4945, a dual PIM1 and casein kinase-2 (CK2) inhibitor, which has undergone Phase I trials in adults with multiple myeloma, breast cancer, and solid tumors. This evidence concerns the gene PIM1 and plasma cell myeloma.